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Type I IFNTwo size forms of ADAR1 adenosine deaminase are known, one constitutively expressed (p110) and the
other interferon (IFN)-induced (p150). To test the role of ADAR1 in viral infection, HeLa cells with ADAR1
stably knocked down and 293 cells overexpressing ADAR1 were utilized. Overexpression of p150 ADAR1 had
no signiﬁcant effect on the yield of vesicular stomatitis virus. Likewise, reduction of p110 and p150 ADAR1
proteins to less than ∼10 to 15% of parental levels (ADAR1-deﬁcient) had no signiﬁcant effect on VSV growth
in the absence of IFN treatment. However, inhibition of virus growth following IFN treatment was ∼1 log10
further reduced compared to ADAR1-sufﬁcient cells. The level of phosphorylated protein kinase PKR was
increased in ADAR1-deﬁcient cells compared to ADAR1-sufﬁcient cells following IFN treatment, regardless of
viral infection. These results suggest that ADAR1 suppresses activation of PKR and inhibition of VSV growth
in response to IFN treatment.
© 2009 Elsevier Inc. All rights reserved.Introduction
Adenosine deaminase acting on RNA (ADAR1) is an RNA editing
enzyme that catalyzes the C-6 deamination of adenosine (A) to
generate inosine (I) in RNA substrates that possess double-stranded
RNA character (Samuel, 2001; Bass, 2002; Valente and Nishikura,
2005; Toth et al., 2006). A-to-I editing is of broad physiologic signi-
ﬁcance, because I is recognized as G instead of A by ribosomes during
translational decoding of mRNA and also by polymerases during RNA-
dependent transcription (Bass, 2002; Toth et al., 2006). Such
substitution A-to-I editing is seen in both cellular and viral RNAs.
The deamination editing can be site-selective, occurring at one or a
few A's, thereby generating protein products with altered function
because of selective amino acid substitutions arising from the
substitution of A with I (G). Among the best characterized examples
of selective editing speciﬁed by imperfect duplex RNA structures are
the hepatitis delta virus antigenome RNA (Luo et al., 1990; Jayan and
Casey, 2002) and the cellular pre-mRNAs for the L-glutamate (GluR)
and serotonin-2c (5-HT2c) receptors in the nervous system (Higuchi
et al., 1993; Liu and Samuel, 1999; Liu et al., 1999; Maas et al., 2001;
Seeburg and Hartner, 2003).Cellular and Developmental
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sites within perfect duplex RNA substrates (Liu and Samuel, 1996;
Kumar and Carmichael, 1997; Liu et al., 2000). Indeed, dsRNA-speciﬁc
adenosine deaminase enzymatic activity was ﬁrst described as a
developmentally regulated dsRNA duplex-unwinding activity in Xe-
nopus oocytes (Rebagliati and Melton, 1987; Bass and Weintraub,
1988). But now it is recognized that, rather than unwinding duplex
dsRNA to separate strands, the RNA becomes more single-stranded in
character because stable A:U base pairs are changed to less stable I:U
base pairs (Bass and Weintraub, 1988; Wagner et al., 1989).
The ADAR1 gene is single copy, ∼40-kbp with 17 exons, and maps
to human chromosome 1q21 (Weier et al., 1995; Liu et al., 1997).
ADAR1 is interferon-inducible (Patterson et al., 1995; George and
Samuel, 1999; George et al., 2008). Two size forms of the ADAR1
protein are known, an IFN-inducible protein of ∼150-kDa designated
p150 that is found in both the cytoplasm and nucleus, and a
constitutively expressed protein of ∼110-kDa designated p110 that
is predominantly if not exclusively a nuclear protein (Patterson and
Samuel, 1995; Toth et al., 2006). At least three alternative promoters,
one of which possesses an ISRE element and is IFN-inducible, together
with alternative splicing, drive the expression of ADAR1 transcripts
with alternative exon 1 structures (George and Samuel, 1999;
Kawakubo and Samuel, 2000; George et al., 2005, 2008). Translation
initiation of the IFN-inducible 1200 amino acid protein (p150) begins
at AUG1 present in the alternative exon 1A at the 5′-termini of IFN-
inducible transcripts, whereas the alternative exon 1B and 1C struc-
tures at the 5′-termini of constitutively expressed ADAR1 transcripts
Table 1
Stable overexpression of ADAR1 p150 or ADAR2 does not affect the single-cycle yield of
vesicular stomatitis virusa.
Cell Time after infection (hours)
4 6 24
(PFU/cell) (PFU/cell) (PFU/cell)
HEK293 220 2200 5600
293-ADAR1wt 420 1000 2800
293-ADAR2wt 520 1600 3200
a Virus yields were measured with the Indiana serotype of VSV in parental HEK 293
cells (HEK 293), and HEK 293 cell clones stably overexpressing either recombinant
ADAR1 p150 (293-ADAR1wt) or ADAR2 (293-ADAR2wt) wild-type protein. Cells were
harvested at the indicated times after infection, and virus yields determined by plaque
titration on mouse ﬁbroblast L cells.
Fig. 1. Stable knockdown of ADAR1 proteins. Western immunoblot analyses comparing
ADAR1 expression in wild-type parental (CONWT), ADAR1 stable knockdown
(ADAR1KD), puromycin-resistant control (CONKD) and PKR stable knockdown
(PKRKD) HeLa cell clones. The large (150 kDa) and the small (110 kDa) size forms of
ADAR1 are designated p150 and p110, respectively. Xrp, a non-speciﬁc cross-reacting
protein migrating just above p150. (A) Whole-cell extract analysis: cells were mock
treated or treated with either 1000 units/ml of IFN-αA/D or IFN-β for 24 h. Whole-cell
extract protein (10 μg) was analyzed in each lane on SDS–10% PAGE. (B) Analysis of
fractionated cell lysates. Cytosolic and nuclear extract fractions were prepared from cells
that had been treated with IFN-β 24 h and analyzed on SDS–7% PAGE. Membranes were
probed using a polyclonal antibody against human ADAR1 and monoclonal antibodies
against β-actin and α-tubulin as loading and fractionation controls (Ahn et al., 2004).
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931 amino acid protein (p110) begins at the in-frame AUG296 present
in exon 2 (George and Samuel, 1999; Valente and Nishikura, 2005;
Toth et al., 2006). A second ADAR gene, ADAR2, maps to human
chromosome 21q22 and encodes an ∼80-kDa RNA adenosine
deaminase that is a nuclear protein. ADAR2 is not regulated by IFN
(Melcher et al., 1996; Villard et al., 1997; Toth et al., 2006).
Both p150 and p110 are active ADAR1 deaminases (Toth et al.,
2006). The p150 and p110 proteins possess, in addition to the
deaminase catalytic domain present in their C-terminal region, three
copies of a dsRNA-binding motif in the central region that is homo-
logous to the dsRNA-binding motif ﬁrst discovered in the RNA-
dependent protein kinase PKR (Kim et al., 1994; O'Connell et al., 1995;
Patterson and Samuel, 1995; Liu and Samuel, 1996). The IFN-inducible
p150protein is N-terminally extended compared to p110, andpossesses
two copies of a Z-DNA binding motif (Patterson and Samuel, 1995;
Athanasiadis et al., 2005). Two viral interferon resistance gene
products that antagonize PKR kinase activity, the vaccinia virus E3L
protein (Chang and Jacobs, 1993; Zhang et al., 2008) and the
adenovirus VAI RNA (Kitajewski et al., 1986), also antagonize
ADAR1 deaminase activity (Lei et al., 1998; Liu et al., 2001).
PKR is well established as an IFN-inducible antiviral protein and an
important component of the IFN innate antiviral defense system
(Haller et al., 2006; Toth et al., 2006; Sadler and Williams, 2008). PKR
is a cytoplasmic RNA sensor; dsRNA and structured single-stranded
RNAs are bound by PKR and mediate autophosphorylation and
activation of PKR (Samuel, 1993). The best characterized substrate
of PKR is the α subunit of translation initiation factor eIF-2, which
when phosphorylated on serine 51, leads to an inhibition of protein
synthesis in IFN-treated infected cells (Samuel, 1979; García et al.,
2006; Sadler and Williams, 2008). Among IFN sensitive viruses is
vesicular stomatitis virus (VSV), a negative-strand RNA virus widely
used in IFN antiviral studies (Samuel, 2001; Haller et al., 2006; Randall
and Goodbourn, 2008). Type I IFNs induce an antiviral state against
VSV characterized by an inhibition of VSV protein production by a
mechanism in which the PKR kinase plays an important role (Masters
and Samuel, 1983; Balachandran et al., 2000; García et al., 2006).
Because PKR is activated by dsRNA, and because ADAR1 acts on
dsRNA, to test whether ADAR1 affects PKR activation and VSV growth,
cells in which N85% of both basal and IFN-inducible ADAR1 protein
expression was stably silenced using a short hairpin RNA interference
approachwere examined. By comparing wild-type parental HeLa cells
and control knockdown HeLa cells that are ADAR1-sufﬁcient with the
ADAR1-deﬁcient knockdown cells, we found that ADAR1 loss did not
affect the growth of VSV in the absence of IFN treatment. Likewise,
overexpression of either ADAR1 or ADAR2 did not affect VSV single-
cycle growth in 293 cells. However, in IFN-treated cells, the loss of
ADAR1 led to enhanced activation of PKR and reduced yields of VSV.
Results
Overexpression of ADAR does not affect vesicular stomatitis virus growth
The single-cycle growth of VSV was examined in HEK 293 cell lines
engineered to overexpress either ADAR1 p150 or ADAR2 protein to
levels ∼7 to 8 fold higher than that of parental 293 cells (Maas et al.,
2001). As shown in Table 1, neither ADAR1 nor ADAR2 overexpression
signiﬁcantly affected VSV multiplication compared to parental 293
cells. The single-cycle yields at 24 h after infection of ADAR1 or ADAR2
overexpressing cells (2800 and 3200 PFU/cell, respectively) differed by
only ∼two-fold from that of the control parental 293 cells (6500 PFU/
cell). Because it was possible that multiple rounds of replication might
be necessary in order to accumulate sufﬁcient mutations resulting from
A-to-I editing to cause a measurable effect on the yield of infectious
progeny, we then passed the virus for ten rounds of growth in 293 cells
that stably overexpressed ADAR1 or ADAR2 as well as in control 293cells. In all three 293 cell lines, the yield of infectious progeny remained
relatively unchanged for three passages, decreased during passages 4
and 5, and then increased during passage 6 and began cycling (data not
shown), a phenomenon described earlier for VSV (Huang and
Baltimore, 1970; Palma and Huang, 1974).
Stable knockdown of cytoplasmic and nuclear ADAR1 proteins
Because overexpression of ADAR1 did not signiﬁcantly affect VSV
multiplication, we next wished to test the effect of ADAR1 p110 and
p150 deﬁciency on virus growth. The HeLa cell clonal line 132 was
examined in which a short hairpin-based RNA interference strategy
was utilized to silence ADAR1 gene expression (Toth et al., 2009). As
measured by Western analysis of whole-cell extracts (Fig. 1A), the
Table 2
Antiviral activity of interferon measured with vesicular stomatitis virus in cells stably
deﬁcient for ADAR1 compared to ADAR1-sufﬁcient cellsa.
Cell Virus yield
Untreated IFN-treated Reduction
(PFU/ml) (PFU/ml) (fold)
CONWT 5.3×107 5.3×105 189
CONKD 3.5×107 1.3×105 276
ADAR1KD 3.0×107 1.4×104 2072
a Virus yields were measured with the Indiana serotype of VSV in wild-type parental
(CONWT), puromycin-resistant control (CONKD), and ADAR1 stable knockdown
(ADAR1KD) HeLa cell clones either untreated or treated with 1000 units/ml IFN-®
prior to infection as described under Materials and methods.
Fig. 2. Steady-state levels of PKR and STAT1 proteins in HeLa clones. Western
immunoblot analyses comparing PKR and STAT1 expression in ADAR1 stable
knockdown (ADAR1KD), wild-type parental (CONWT), puromycin-resistant control
(CONKD, CONKD2) and PKR stable knockdown (PKRKD) HeLa cell clones. Cells were left
untreated or treated with IFN-αA/D for 24 h, whole-cell extracts were prepared,
fractionated on SDS–10% PAGE (20 μg protein per lane), and membranes probed with
antibodies against (A) STAT1 and (B) PKR. β-actin was used as a loading control.
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showed b15% of p110 ADAR1 protein, and b10% of p150 ADAR1
protein, compared to the levels seen in ADAR1-sufﬁcient HeLa cell
lines. Three different ADAR1-sufﬁcient lines were used as controls:
the parental HeLa cells (CONWT), a negative control puromycin-
resistant clone shRNA pSUPER.retro.puro (CONKD), and the HeLa cell
clone (designated PKRKD) which is stably knocked down for PKR
expression (Zhang and Samuel, 2007). While both IFN-α and IFN-β
induced p150 ADAR1 in the CONWT, CONKD and PKRKD cells, the level
of p150 ADAR1 remained very low in the ADAR1KD cells even after
treatment with type I IFN α or β (Fig. 1A).
When separate cytoplasmic and nuclear subcellular fractions were
analyzed from IFN-β treated cells (Fig. 1B), the p110 ADAR1 protein
was found predominantly if not exclusively in the nuclear fraction,
whereas the p150 protein was found in both the cytoplasmic and
nuclear fractions as originally described (Patterson and Samuel,
1995). The stable shRNAi knockdown of ADAR1 reduced the level of
p150 ADAR1 to nearly an undetectable level, both in the cytoplasmic
and the nuclear subcellular fractions. The protein cross-reacting with
ADAR1 antiserum (Xrp) that migrated slightly more slowly than p150
on SDS–PAGE was a cytoplasmic protein, and was not reduced by the
ADAR1 knockdown (Fig. 1B).
The ADAR1 targeting region for the knockdown is located in the
ADAR1 3′-UTR corresponding to nt positions 4782–4802 (Toth et al.,
2009), with the A of AUG1 taken as +1 in the ADAR1 sequence
U18121 (Patterson and Samuel, 1995). The ﬁnding that both the
inducible p150 and the constitutive p110 ADAR1 proteins were stably
knocked down by the single shRNAi that targeted the 3′-UTR se-
quence is consistent with the conclusion that structures of the indu-
cible transcript encoding p150 and the constitutively expressed
transcript encoding p110 differ only in their alternative exons 1 and
7, but otherwise are identical including the 3′-UTR (George and
Samuel, 1999; George et al., 2005). Finally, in the PKRKD cells, the
level of ADAR1was comparable to the control CONWT and CONKD cells
(Figs. 1A, B).
Effect of ADAR1 deﬁciency on cell growth
Two tests were performed to assess whether the stable knock-
down of ADAR1 affected cell growth in culture, either in the absence
or presence of treatment with IFN-β. First, as measured by direct cell
count during subconﬂuent growth in monolayer culture, there was no
signiﬁcant difference in growth rate between the CONWT and CONKD
cells either untreated or treated with IFN-β and the ADAR1KD cells in
the absence of IFN treatment. By contrast, over a 48 h period in the
presence of IFN-β, for ADAR1KD cells there was a signiﬁcant
(pb0.001student t-test) reduction in cell number, ∼60%, compared
to untreated cultures (data not shown).
The cell cycle distribution was next examined. As determined by
propidium iodide staining to measure DNA content, the cell cycle
distribution during subconﬂuent growth in monolayer culture was
comparable for the ADAR1KD and the ADAR1-sufﬁcient CONKD cells.
About 45–50% of the cells were in G0/G1, about 20% of the cells were in
S, and about 30% in G2/M. As a control, thymidine-block CONKD cells
showed a substantially increased number of cells in S phase and
decreased number in G0/G1.
Effect of ADAR1 deﬁciency on vesicular stomatitis virus growth and
interferon sensitivity
Little is known regarding the effect that loss of ADAR1 has on virus
replication and the antiviral action of interferon in human cells. To
begin to address this question, we ﬁrst tested the ability of VSV, a
widely utilized virus in IFN studies, to multiply in ADAR1KD compared
to ADAR1-sufﬁcient (CONWT, CONKD) cells. As shown in Table 2, VSV
yields in the absence of IFN treatment were comparable in theADAR1KD cells and the two ADAR1-sufﬁcient HeLa cell lines. However,
treatment of cells with IFN consistently reduced the yield of infectious
VSV to a lower level in the ADAR1KD cells compared to ADAR1-
sufﬁcient cells (Table 2). The yield of infectious VSV was reduced
about 200- to 300-fold by IFN-β treatment of the parental CONWT and
control CONKD ADAR1-sufﬁcient lines. By contrast, the antiviral state
was enhanced in ADAR1KD cells. Treatment of ADAR1KD cells with IFN-
β gave a reduction of about 2000-fold in VSV yield, typically ∼1 log10
further inhibition than that seen in either ADAR1-sufﬁcient cell line. In
four independent experiments, the VSV yield in IFN-treated ADAR1KD
cells was about 16.5-fold less than in IFN-treated ADAR1-sufﬁcient
control cells. These results indicate that ADAR1 has a negative or
suppressing effect on the establishment of an antiviral state against
VSV.
Stable knockdown of ADAR1 does not affect the expression level of PKR
or STAT1 proteins
The basal and inducible expression levels of two other type I IFN-
regulated proteins, STAT1 (Fig. 2A) and PKR (Fig. 2B), were assessed
by Western analysis of ADAR1-deﬁcient compared to ADAR1-
sufﬁcient cells. As shown in Fig. 2, neither PKR nor STAT1 steady-
state protein level was affected by the knockdown of ADAR1. Like-
wise, the levels of β-actin and α-tubulin were unaffected in the
Fig. 4. Vesicular stomatitis virus infection does not alter the steady-state level of PKR or
eIF-2α proteins in ADAR1KD cells. Western immunoblot analyses comparing PKR and
eIF-2α expression in wild-type parental (CONWT), puromycin-resistant control
(CONKD), PKR stable knockdown (PKRKD), and ADAR1 stable knockdown (ADAR1KD)
HeLa cell clones, either mock treated (–, lanes 1–8) or treated with 1000 units/ml IFN-β
for 16 h (+, lanes 9–16) prior to infection with VSV (+) or were left uninfected (–).
Whole-cell extracts were prepared at 8 h after infection, fractionated on SDS–7% PAGE
(20 μg protein per lane), and analyzed by western immunoblot utilizing antibodies
against PKR, eIF-2α, and β-actin.
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sufﬁcient cell lines, CONWT, CONKD and ADAR1KD, were comparable,
whereas the PKRKD stable knockdown clone had b5% of the PKR
protein level seen in the PKR-sufﬁcient parental cells as previously
described (Zhang and Samuel, 2007).
ADAR1 deﬁciency leads to enhanced PKR activation
Because the antiviral activity of IFN against VSV was enhanced in
the ADAR1-deﬁcient cells (Table 2), and because ADAR1 binds
dsRNA (Liu and Samuel, 1996; Toth et al., 2006) and furthermore
because ADAR1 was discovered based on its dsRNA-destablizing
activity (Bass and Weintraub, 1988; Rebagliati and Melton, 1987),
we considered the possibility that ADAR1 acts in part through
modulation of PKR kinase activation which is mediated by RNA
with double-stranded character (Toth et al., 2006; Sadler and
Williams, 2008). To test this possibility, the effect of ADAR1 knock-
down on PKR activation status measured by phosphorylation at
threonine 446 was determined in VSV-infected cells that had been
treated with IFN-β or not (Fig. 3). The human PKR protein is
autosphosphorylated on multiple serine and threonine residues,
one of which is T446, and these phosphorylations cause a decrease
in electrophoretic mobility of PKR (Thomis and Samuel, 1993;
Samuel, 2001).
In the cells stably knocked down for ADAR1 (ADAR1KD) and
treated with IFN, PKR phosphorylation at T446 was enhanced
compared to the ADAR1-sufﬁcient CONKD cells (Fig. 3, lane 19
compared to lane 11). Transient knockdown of ADAR1 in the CONKD
cells by transfection with chemically synthesized siRNA against
ADAR1 also led to increased PKR phosphorylation (lane 13) com-
pared to an siRNA against luciferase (Luc) as a control (lane 12). Cells
stably knocked down for PKR expression (PKRKD), and either
subsequently transiently knocked down for ADAR1 or not, did not
show a detectable PKR T446 phosphorylation signal (Fig. 3, lanes 15–
18). The level of PKR protein was comparable in the CONKD and
ADAR1KD cells (Fig. 3, lanes 1–2, 9–10) in the absence of IFN treat-
ment as earlier shown (Fig. 2B). Surprisingly, the enhanced PKR
phosphorylation at T446 observed in VSV-infected cells in which
ADAR1 was either stably (lanes 19, 20) or transiently (lane 13)
knocked down was dependent upon treatment with IFN; parallel
cultures that were left untreated (lanes 3, 9, 10) did not show the
enhanced PKR activation irrespective of ADAR1 knockdown, either
stable or transient (Fig. 3).Fig. 3. Effect of ADAR1 knockdown either stably or transiently on activation of PKR kinase. A
resistant control (CONKD)HeLa cell cloneswere subsequently transiently knocked downutiliz
or PKR (siPKR) as described under Materials and methods. Following transient knockdown,
1000 units/ml IFN-β for 16 h (+, lanes 11–20) prior to infection with VSV.Whole-cell extrac
lane), and analyzed by western immunoblot analysis utilizing antibodies against PKR and pWe next tested whether VSV infection altered the steady-state
protein level of either PKR or eIF-2α in ADAR1KD cells compared to
ADAR1-sufﬁcient cells. As shown in Fig. 4, the level of PKR protein
was comparable in CONWT, CONKD and ADAR1KD cells, both uninfected
cells (lanes 1–4) and cells infected for 8 h (lanes 5–8), all in the
absence of IFN treatment. IFN treatment prior to infection led to
comparably increased levels of PKR protein in all three of these
PKR-sufﬁcient cell lines, but did not alter the level of the eIF-2α factor
(Fig. 4). In the PKRKD cells, the PKR protein was marginally detectable
even after IFN treatment (Fig. 4, lanes 3, 7, 11, 15) as previously des-
cribed (Zhang et al., 2008). However, serine 51 phosphorylation of
eIF-2α was increased in VSV-infected IFN-treated ADAR1KD cells
(Fig. 5, lane 4) compared to the ADAR1-sufﬁcient CONWT and CONKD
cells where the eIF-2αS51 phosphorylation was comparable to PKRKD
cells (Fig. 5, lanes 1–3). These results suggest that the depletion of
ADAR1 leads to enhanced activation of PKR as measured by T446
phosphorylation in VSV-infected cells, and that the increased PKR
phosphorylation is dependent upon IFN treatment. Furthermore, the
elevated phosphorylation of PKR seen in the ADAR1-deﬁcient IFN-
treated VSV-infected cells (Fig. 3) correlates with the enhanced anti-
viral activity (further reduced yields of VSV) found in the ADAR1KD
cells compared to ADAR1-sufﬁcent cells (Table 2) and increased
eIF-2α phosphorylation (Fig. 5).DAR1 stable knockdown (ADAR1KD), PKR stable knockdown (PKRKD) and puromycin-
ing chemically synthesized siRNAs against luciferase (siLuc) as a control, ADAR1 (siAD1),
the cells in monolayer culture were either mock treated (–, lanes 1–10) or treated with
ts were prepared at 8 h after infection, fractionated on SDS–10% PAGE (30 μg protein per
hospho-threonine 446 PKR (P-PKR). β-actin was used as a loading control.
Fig. 5. ADAR1 knockdown leads to increased phosphorylation of protein synthesis
initiation factor eIF-2α. Wild-type parental (CONWT), puromycin-resistant control
(CONKD), PKR stable knockdown (PKRKD), and ADAR1 stable knockdown (ADAR1KD)
HeLa cell clones were treated with 1000 units/ml IFN-β for 16 h, and then infected with
VSV for 8 h. Whole-cell extracts were prepared, fractionated on SDS–7% PAGE (30 μg
protein per lane), and analyzed by western immunoblot analysis for the T446
phosphorylation of PKR (P-PKR), S51 phosphorylation of eIF-2α (P-eIF2α), and β-actin.
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In this study we used human cell lines in which N85% of ADAR1
was stably depleted by an RNA interference strategy, and cell lines
stably overexpressing ADAR1 or ADAR2, to investigate the roles of
ADAR1 in both cell growth and virusmultiplication. Several important
points emerge from our ﬁndings.
First, the substantial reduction of ADAR1 proteins, both basal p110
and IFN-inducible p150, achieved in the ADAR1KD cells did not
signiﬁcantly affect either cell growth or vesicular stomatitis virus
replication in culture in the absence of IFN treatment. VSV grew
comparably well in ADAR1KD and ADAR1-sufﬁcient cells when left
untreated with IFN. Likewise, overexpression of either ADAR1 p150 or
ADAR2 did not affect VSV single-cycle virus yields. The ADAR1KD cells,
however, were more sensitive to the antiviral actions of type I IFN
than the parental CONWT and the knockdown control CONKD ADAR1-
sufﬁcient cells. What molecular mechanism might account for the
further reduction in VSV growth seen in the IFN-treated ADAR1KD
cells compared to CONWT or CONKD ADAR1-sufﬁcient cells?
PKRwas found to be an important component of the IFN-mediated
resistance to VSV infection in earlier studies using either the catalytic
domain disrupted Pkr knockout mice and derived Pkr null MEF cells
(Stojdl et al., 2000) or human HeLa cells in which PKR was stably
knocked down (PKRKD) by a short hairpin RNA interference strategy
(Zhang and Samuel, 2007). In the absence of IFN treatment, VSV yields
are comparable in PKRKD and CONKD HeLa cells, but in IFN-treated
PKRKD cells the yield reduction is modestly different, only ∼10–30 fold
in PKRKD compared to ∼100–300 fold in CONKD cells (Zhang and
Samuel, 2007), similar to the reduction observed herein in CONKD cells
(Table 2). We therefore considered the possibility that ADAR1 may
exert a suppressive modulatory effect on PKR that is relieved in the
ADAR1 knockdown cells. Indeed, ADAR1 binds dsRNA and through A-
to-I RNA editing destabilizes dsRNA structures (Liu and Samuel, 1996;
Toth et al., 2006), the very property by which ADARs were originally
discovered (Rebagliati and Melton, 1987; Bass and Weintraub, 1988).By contrast, PKR is activated by RNA with double-stranded character
(Samuel, 1979). We found that the activation of PKR as measured by
T446 phosphorylation was increased in IFN-treated ADAR1KD cells,
and furthermore, that this increased activation of PKR correlated with
a reduced virus growth in IFN-treated ADAR1KD cells compared to
ADAR1-sufﬁcient cells. Although transient overexpression of ADAR1
also has been reported to enhance VSV replication and to impair
phosphorylation of PKR and eIF-2α (Nie et al., 2007), we were unable
to conﬁrm this observation using HEK293 cells stably overexpressing
either ADAR1 p150 or ADAR2. Curiously the reported proviral effect of
ADAR1 overexpression was dependent upon the N-terminal RNA-
binding domains but not the catalytic deaminase domain of ADAR1
(Nie et al., 2007; Clerzius et al., 2009). However, it is known that such
an RNA-binding domain dependent response is not unique to ADAR1.
Other dsRNA-binding proteins, as illustrated by vaccinia virus E3L,
reovirus σ3 and TAR RNA-binding protein, also are known to anta-
gonize PKR activation and enhance virus growth (Haller et al., 2006;
Randall and Goodbourn, 2008; Samuel, 2001; Zhang et al., 2008).
Genetic disruption of Adar1 in mice is embryonic lethal at E11.5–
12.5 and occurs with liver disintegration (Hartner et al., 2004; Wang
et al., 2004). ADAR1 is essential for the maintenance of hematopoietic
stem cells, and genetic loss of ADAR1 leads to up regulation of type I
and type II IFN-inducible transcripts in hematopoietic stem cells but
not other cells (Hartner et al., 2009). Our results are in agreement
with these observations. We found that ADAR1 knockdown in HeLa
cells did not affect either PKR or STAT1 induction by type I IFN, and
Hartner et al. (2009) found that ADAR1 genetic deﬁciency likewise
did not affect STAT1 transcript levels in macrophages or neutrophils.
These observations taken together suggest that ADAR1 likely
mediates effects on IFN signaling, and possibly cell growth, in a
cell-speciﬁc manner. We have described a PKR-dependent induction
of IFN-β and apoptosis in cells transfected with dsRNA (McAllister
and Samuel, 2009), and PKR transcripts are reported to be up
regulated in ADAR1-deﬁcient hematopoietic stem cells (Hartner
et al., 2009). Conceivably such an ADAR1-mediated modulation of
PKR induction and activation contributes to the apoptosis and early
embryonic lethality seen in mice (Hartner et al., 2004, 2009; Wang
et al., 2004).
One surprising observation in our study was that type I IFN
treatment alone was sufﬁcient to mediate enhanced activation of PKR
in ADAR1-deﬁcient cells, both in cells stably knocked down or cells
transiently knocked down for ADAR1 protein. VSV infection was not
required in addition to the IFN-β treatment. An intriguing possibility
is that the IFN treatment leads to induction of cellular transcripts with
the capacity to activate PKR, and that these transcripts also are
substrates for modiﬁcation by ADAR1. The best characterized ADAR1
cellular substrate RNAs with double-stranded character, predomi-
nantly neurotransmitter receptors and channels, are not known to be
IFN-regulated (Samuel, 2001), although computational analyses
have identiﬁed a number of additional candidate cellular RNA targets
for A-to-I editing (Toth et al., 2006). Possibly one or more of these are
IFN-inducible, and capable of PKR activation.
Type I IFN treatment induces expression of both PKR (Tanaka and
Samuel, 1994; Kuhen and Samuel, 1997) and the p150 size form of
ADAR1 (Patterson and Samuel, 1995; George and Samuel, 1999;
2008). p150 ADAR1, like PKR, is found in the cytoplasm of IFN-treated
cells (Toth et al., 2006). It is tempting to speculate that one function of
the IFN-inducible ADAR1 dsRNA-editing enzyme is to suppress RNA-
dependent activation of the IFN-inducible PKR kinase. That ADAR1 has
a positive effect on virus replication through suppression of PKR, as
we observe for VSV herein under conditions of IFN treatment, also has
been observed with two other RNA viruses with vastly different
replication strategies, human immunodeﬁciency virus (Clerzius et al.,
2009; Doria et al., 2009) and measles virus (Toth et al., 2009).
Whether the counter-balancing effect of one IFN-inducible enzyme
(ADAR1) on another (PKR) is signiﬁcant in PKR-modulated biologic
321Z. Li et al. / Virology 396 (2010) 316–322responses in addition to virus replication, for example apoptosis and
signaling, remains to be established.
Materials and methods
Cells and viruses
HeLa cells, 293 human embryonic kidney (HEK) cells and mouse
ﬁbroblast L cells were maintained in Dulbecco's modiﬁed Eagle's
medium supplemented with 10% (v/v) fetal bovine serum (HyClone),
100 μg/ml of penicillin, and 100 units/ml of streptomycin (GIBCO/
Invitrogen) as previously described (Zhang and Samuel, 2007). HeLa
cells stably knocked down for either PKR (“PKRKD”) (Zhang and
Samuel, 2007; Zhang et al., 2008) or ADAR1 (“ADAR1KD”) (Toth et al.,
2009) established using a short hairpin RNA interference strategy,
and drug-resistant knockdown controls cells (“CONKD”), were main-
tained in the above-named maintenance medium containing 1 μg/ml
puromycin (Sigma). The HeLa cell parental line was sometimes used
as an additional control and is designated as CONWT. HEK 293 cell lines
stably overexpressing ADAR1 or ADAR2 (Maas et al., 2001) were
generously provided by S. Maas and A. Rich (MIT, Cambridge, MA).
The Indiana serotype of vesicular stomatitis virus (VSV) was as pre-
viously described (Samuel and Knutson, 1981; Zhang and Samuel,
2007). Interferon treatment was with 1000 units/ml of recombinant
IFN, either IFN-αA/D (PBL InterferonSource) or IFN-β (Toray Indus-
tries), for 16 h unless otherwise as indicated.
Transient knockdown
Transient knockdown of either PKR or ADAR1 in human cells was
carried out using chemically synthesized siRNAs. The siRNAs were
obtained from Dharmacon with dTdT overhangs and the following
sequences: PKR, sense strand 5′-GCAGGGAGUAGUACUUAAAATT-3′
(Zhang and Samuel, 2007) and ADAR1, sense strand 5′-CGCAGAGUU-
CCUCACCUGUATT-3′ (Jayan and Casey, 2002). Transfection of siRNAs
was performed with lipofectamine 2000 (Invitrogen) following the
manufacturer's protocol. Two cycles of transient transfection were
necessary to achieve maximal transient knockdown of ADAR1 in the
HeLa cells stably knocked down for PKR, and conversely transient
knockdown of PKR in the cells stably knocked down for ADAR1.
Brieﬂy, nearly conﬂuent cells were transfected with siRNA targeting
ADAR1 on day 1, then on day 2 the cells were split and seeded at 60%
conﬂuence. On day 4 the cells were transfected again with the
appropriate siRNA and then tested for phenotype 36 to 48 h later.
Interferon treatment was with 1,000 units/ml of either IFN-αA/D or
IFN-β indicated.
Virus infections and growth assays
ADAR1KD, CONKD, and/or CONWT cells were infected with vesicular
stomatitis virus at anMOI of 0.5 or 10 as indicated. Virus adsorption in
monolayer culture was carried out in Puck's saline A modiﬁed to
contain 10 mM MgCl2 and 1% (v/v) fetal bovine serum. After 1 h the
inoculumwas removed, themonolayers rinsed twice, and the cultures
then incubated in maintenance medium with 5% (v/v) serum.
Infected cultures were harvested at the indicated time postinfection
by scraping the infected cells into the medium. Virus yields were
determined by plaque titration, using mouse L cells (Samuel and
Knutson, 1981; Zhang and Samuel, 2007).
Western immunoblot analyses
Whole-cell extracts, and cytosolic and nuclear fractions, were
prepared in the presence of 1 mM phenylmethylsulfonyl ﬂuoride
and 1% (v/v) protease inhibitor mixture (Sigma) as previously des-
cribed (Das et al., 2006; Zhang and Samuel, 2007). For analysis of PKRand eIF-2α phosphorylation status, lysis buffers were supplemented
1% (v/v) phosphatase inhibitor cocktail (Sigma). Protein concentra-
tion of the extract fractions was determined by the Bradford method.
Proteins were fractionated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) using either 7% or 10% acrylamide
gels as indicated, transferred to nitrocellulose, and the membranes
blocked in Tris-buffered saline containing either 5% (w/v) bovine
serum albumin (for detection of phospho proteins) or skim milk (for
detection of other proteins). Rabbit polyclonal antibody against
ADAR1 (K88#2) was previously described (Patterson and Samuel,
1995). Rabbit polyclonal antibodies from the indicated sources were
used to detect humanPKR (Santa Cruz), eIF-2α (Cell Signaling), eIF-2α
phosphorylated at Ser51 (Cell Signaling), and STAT-1 (Santa Cruz).
Either rabbit polyclonal (Santa Cruz) or monoclonal (Epitomics)
antibody was used to detect PKR phosphorylated at Thr446.
Mouse monoclonal antibodies were used to detect FLAG epitope-
tagged ADAR (Sigma), β-actin (Sigma), and α-tubulin (Sigma). Blot
detection was performed with IRDye 800CW-conjugated anti-rabbit
IgG or IRDye 680-conjugated anti-mouse IgG secondary antibody ac-
cording to the manufacturer's protocols (Li-Cor Biosciences). Immu-
noreactive bands were visualized using a Li-Cor Odyssey infrared
imaging system.
Cell cycle analyses
HeLa cell clones, knockdown or control as indicated, were cultured
in maintenance medium and either left untreated or treated with
IFN-β at 1000 units/ml for 24 h. Cells were analyzed at ∼70% con-
ﬂuence in monolayer. For cell cycle analyses, cells were ﬁxedwith 70%
ethanol overnight, rinsed with PBS, and then treated with RNase A
(200 μg/ml) for 30 min at 37°C. After staining with propidium iodide
(10 μg/ml, Sigma), the percentages of cells in G0/G1, S, and G2/M
were determined using a Guava Technologies Easy Cyte instrument
and CytoSoft software. Double thymidine block-treated samples
(Sansregret et al., 2006) were used as a positive control.
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